Evidence map›Paper›PMID 23847414›Full record

ReviewInternational journal of chronic obstructive pulmonary disease2013

The association between COPD and heart failure risk: a review.

Javier de Miguel Díez, Jorge Chancafe Morgan, Rodrigo Jiménez García

Registry-linked trialAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of chronic obstructive pulmonary disease, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04994574 (Effects of Tiotropium/Olodaterol on Cardio-pulmonary Exercise Capacity in Patients With Hyperinflated Chronic Obstructive Pulmonary Disease [ACHIEVE]), which is not on this map. Cited by 79 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
79citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04994574 nacompletednot on this mapstarted 2021, after this paper: background citation

Effects of Tiotropium/Olodaterol on Cardio-pulmonary Exercise Capacity in Patients With Hyperinflated Chronic Obstructive Pulmonary Disease [ACHIEVE]

TypeinterventionalSponsorYonsei UniversityRan2021 to 2024Enrolled44ConditionsChronic Obstructive Pulmonary DiseaseArmstiotropium/olodaterol
3 · Its place in the literature

Who cites it

79 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Physiological signal entropy in patients with chronic respiratory disease: a systematic review.European respiratory review : an official journal of the European Respiratory Society · 2025
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Chronic Obstructive Pulmonary Disease and the Risk of Stroke.Annals of the American Thoracic Society · 2017
    Pooled it
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Observational
  16. Article
  17. Article
  18. Influence of Secondary Metabolites According to Maturation of Perilla (International journal of molecular sciences · 2024
    Article
  19. Article
  20. Article

19 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Javier de Miguel DíezPulmonology Department, Gregorio Maranon University Hospital, Complutense University of Madrid, Madrid, Spain. jmiguel.hgugm@salud.madrid.org
Jorge Chancafe Morgan
Rodrigo Jiménez García

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic obstructive pulmonary disease (COPD) is commonly associated with heart failure (HF) in clinical practice since they share the same pathogenic mechanism. Both conditions incur significant morbidity and mortality. Therefore, the prognosis of COPD and HF combined is poorer than for either disease alone. Nevertheless, usually only one of them is diagnosed. An active search for each condition using clinical examination and additional tests including plasma natriuretic peptides, lung function testing, and echocardiography should be obtained. The combination of COPD and HF presents many therapeutic challenges. The beneficial effects of selective β1-blockers should not be denied in stable patients who have HF and coexisting COPD. Additionally, statins, angiotensin-converting enzyme inhibitors, and angiotensin-receptor blockers may reduce the morbidity and mortality of COPD patients. Moreover, caution is advised with use of inhaled β2-agonists for the treatment of COPD in patients with HF. Finally, noninvasive ventilation, added to conventional therapy, improves the outcome of patients with acute respiratory failure due to hypercapnic exacerbation of COPD or HF in situations of acute pulmonary edema. The establishment of a combined and integrated approach to managing these comorbidities would seem an appropriate strategy. Additional studies providing new data on the pathogenesis and management of patients with COPD and HF are needed, with the purpose of trying to improve quality of life as well as survival of these patients.

Indexed as

Heart FailurePulmonary Disease, Chronic ObstructiveAdrenergic beta-1 Receptor AntagonistsAdrenergic beta-2 Receptor AgonistsCardiovascular AgentsComorbidityContraindicationsDisease ManagementEchocardiographyHumansHydroxymethylglutaryl-CoA Reductase InhibitorsNatriuretic PeptidesNoninvasive VentilationRespiratory Function TestsAdrenergic beta-1 Receptor AntagonistsAdrenergic beta-2 Receptor AgonistsCardiovascular AgentsHydroxymethylglutaryl-CoA Reductase InhibitorsNatriuretic Peptideschronic obstructive pulmonary diseaseheart failure

Identifiers

PMID23847414
PMCPMC3700784

What OpenQuestion holds

Texttitle and abstract
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.